Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study
Nutrients · 2024
DOI: 10.3390/nu16223857 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von José Ignacio Martínez-Montoro und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, 29010 Málaga, Spain. Hauptthemen laut MEDLINE: Weight Loss, Gastrectomy, Liver, Fatty Liver. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health and Families of Junta de Andalucía, Instituto de Salud Carlos III, Madrid, Spain, FEDER.
Abstract (Originalsprache)
Background
The role of metabolic dysfunction-associated steatotic liver disease (MASLD) in sleeve gastrectomy (SG)-related outcomes remains uncertain. In this study, we aimed to assess the influence of preoperative biopsy-proven MASLD and its stages on weight loss after SG.
Methods
One hundred sixty-three patients with obesity undergoing SG with concomitant intraoperative liver biopsy were followed up for 1 year. Fifty-eight participants were categorized as no MASLD, thirty-eight as metabolic dysfunction-associated steatotic liver (MASL), and sixty-seven as metabolic dysfunction-associated steatohepatitis (MASH). Percentage total weight loss (%TWL) and percentage excess weight loss (%EWL) 1 year after SG were calculated for the different groups. We also evaluated the association between preoperative MASLD (and its stages) and weight loss, after adjusting for potential confounders.
Results
Significant differences among groups were detected in %EWL (p = 0.004, ANOVA test), but not in %TWL (p = 0.079). However, significant differences in %TWL were found when MASH and no MASH (i.e., participants with MASL and participants without MASLD) groups were compared (27.3 ± 9.9 vs. 30.7 ± 9, respectively, p = 0.025). In the linear regression model for predicting %EWL 1 year after SG, the presence of MASH was independently associated with a lower %EWL, after adjusting for age, sex, baseline body mass index (BMI), and baseline glycated hemoglobin (HbA1c) (Beta −7.1; 95% CI −13.6, −0.5; p = 0.035). The presence of MASLD, liver fibrosis, or advanced liver fibrosis (≥F2) was also associated with lower %EWL after SG in crude models, although they did not remain significant after adjusting for these confounders. The presence of MASH was inversely related to %TWL, although the association did not remain significant after adjustment (Beta −2.7; 95% CI −5.7, 0.2; p = 0.069).
Conclusions
MASH may be independently associated with lower %EWL 1 year after SG in patients with obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, Virgen de la Victoria University Hospital, 29010 Málaga, Spain.
- Instituto de Investigación Biomédica de Málaga (IBIMA-Plataforma BIONAND), 29010 Málaga, Spain.
- Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 28029 Madrid, Spain.
- Department of Anatomical Pathology, Virgen de la Victoria University Hospital, 29010 Málaga, Spain.
- Department of Human Physiology, Human Histology, Anatomical Pathology and Physical Education, University of Málaga, 29010 Málaga, Spain.
- Department of General and Digestive Surgery, Virgen de la Victoria University Hospital, 29010 Málaga, Spain.
ORCID-Profile: José Ignacio Martínez-Montoro, José M Pinazo-Bandera, Araceli Muñoz-Garach, Dieter Morales-García, Miren García-Cortés
Förderung
- Ministry of Health and Families of Junta de Andalucía
- Instituto de Salud Carlos III, Madrid, Spain
- FEDER
- Rio Hortega grant from Instituto de Salud Carlos III, Madrid, Spain
- Nicolas Monardes program from Consejería de Salud de Andalucía (Spain)
- Miguel Servet program from Instituto de Salud Carlos III
Zitieren
APA
Martínez-Montoro, J. I., Arranz-Salas, I., Gutiérrez-Repiso, C., Sánchez-García, A., Ocaña-Wilhelmi, L., Pinazo-Bandera, J. M., Fernández-García, D., Muñoz-Garach, A., Morales-García, D., García-Cortés, M., García-Fuentes, E., Tinahones, F. J., & Garrido-Sánchez, L. (2024). Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study. Nutrients. https://doi.org/10.3390/nu16223857
Vancouver
Martínez-Montoro JI, Arranz-Salas I, Gutiérrez-Repiso C, Sánchez-García A, Ocaña-Wilhelmi L, Pinazo-Bandera JM, et al. Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study. Nutrients. 2024. doi:10.3390/nu16223857
BibTeX
@article{MartnezMontoro2024,
author = {Martínez-Montoro, José Ignacio and Arranz-Salas, Isabel and Gutiérrez-Repiso, Carolina and Sánchez-García, Ana and Ocaña-Wilhelmi, Luis and Pinazo-Bandera, José M and Fernández-García, Diego and Muñoz-Garach, Araceli and Morales-García, Dieter and García-Cortés, Miren and García-Fuentes, Eduardo and Tinahones, Francisco J and Garrido-Sánchez, Lourdes},
title = {Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study},
journal = {Nutrients},
year = {2024},
doi = {10.3390/nu16223857}
}
EUVIMED